MedTrace Logo

Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

NCT00064220 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-05-16

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of soblidotin in treating patients who have advanced or metastatic soft tissue sarcoma.

Conditions

  • Sarcoma

Interventions

DRUG

soblidotin

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Daiichi Sankyo

    lead INDUSTRY

Principal Investigators

  • Juan Pagan · Daiichi Sankyo

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00064220 on ClinicalTrials.gov